Canadian rapid diagnostics firm MedMira has entered a distribution agreement with VWR International that it says will help it reach several important U.S. industries. Per this agreement, VWR will be selling MedMira’s Miriad platform technology as well as its Reveal G3 rapid HIV test. The two companies also aim to add more rapid testing products to MedMira’s portfolio in the future.

“This agreement is a cornerstone of the foundation for MedMira’s future strategy,” said Kevin Jones, Ph.D., MedMira’s senior director of global sales and marketing, in a statement. “VWR has more than 300 U.S. representatives on the ground every day, in laboratories, universities, and businesses in a variety of industries. We are thrilled and committed to work alongside VWR to bring our technologies and solutions to a much broader U.S. user base than we previously were able to reach.”

MedMira has won several USAMRAA contracts tapping its expertise in rapid testing, the most recent one, said to be worth around $1.917 million, it received last October toward developing and commercializing two rapid tests for transfusion-transmitted diseases.

Previous articleAlexion, Moderna to Develop Rare Disease-Fighting mRNA Therapeutics
Next articleRegeneron, Bayer Ink Potentially $65M+ Wet AMD Combo Treatment Deal